LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 8 von insgesamt 8

Buch: Stroke genomics

Read, Simon J.

methods and reviews

(Methods in molecular medicine ; 104)

2005

Verfasserangabe	ed. by Simon J. Read
Serientitel	Methods in molecular medicine ; 104
Überordnung
Schlagwörter	Cerebrovascular Accident / genetics
Sprache	Englisch
Umfang	X, 351 S. : Ill., graph. Darst.
Verlag	Humana Press
Erscheinungsort	Totowa, NJ
Erscheinungsland	Vereinigte Staaten
Dokumenttyp	Buch
HBZ-ID	HT014040946
ISBN	1-58829-333-5 ; 978-1-58829-333-6
Datenquelle	Katalog ZB MED Medizin, Gesundheit

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Signatur	Leihstatus	Standort
2005 A 4136	bestellbar zur Ausleihe	Magazin

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Buch: Stroke genomics

Read, Simon J / Virley, David

methods and reviews

(Methods in molecular medicine, ; 104)

2005

Verfasserangabe	edited by Simon J. Read, David Virley
Serientitel	Methods in molecular medicine, ; 104
Mesh-Begriff(e)	Stroke/genetics
Sprache	Englisch
Umfang	x, 351 p. :, ill.
Verlag	Humana Press
Erscheinungsort	Totowa, N.J
Dokumenttyp	Buch
ISBN	9781588293336 ; 1588293335 ; 9781592598366 ; 1592598366
Datenquelle	Katalog der US National Library of Medicine (NLM)

Zusatzmaterialien

Über subito bestellen

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Osteoarthritic pain: a review of current, theoretical and emerging therapeutics.

Read, Simon J / Dray, Andy

Expert opinion on investigational drugs

2008 Band 17, Heft 5, Seite(n) 619–640

Abstract: Background: Despite exciting progress and growth in the understanding of molecular and cellular mechanisms of chronic pain, osteoarthritis (OA) pain remains a challenging clinical entity to treat. There is an emerging diversity of algogenic mechanisms ... ...

Abstract	Background: Despite exciting progress and growth in the understanding of molecular and cellular mechanisms of chronic pain, osteoarthritis (OA) pain remains a challenging clinical entity to treat. There is an emerging diversity of algogenic mechanisms suggesting heterogeneity in pain aetiology in the OA patient population. Objective/methods: This review article summarises key issues in existing therapies for OA pain and highlights the emerging compounds in early and late development. It also highlights where tolerability may be a concern, especially in the older populations in which treatment interactions for co-morbid conditions may further narrow therapeutic index. Importantly, the authors also examine the diversity of biology that underpins OA pain and highlight the opportunities for the future. Results/conclusions: Many emerging therapies are presently in proof-of-concept clinical testing for treatment of OA. A growing understanding of the heterogeneity in the OA patient population, will challenge the ability to accurately understand observed efficacy or safety signals in these relatively small trials and how they may titrate to a broader patient population. We may need to wait several more years to understand whether the need for a differentiated therapy demanded by patients, payors and physicians alike, will be met.
Mesh-Begriff(e)	Analgesics, Opioid/administration & dosage ; Analgesics, Opioid/therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Bone and Bones/drug effects ; Bone and Bones/metabolism ; Bone and Bones/pathology ; Cannabinoids/administration & dosage ; Cannabinoids/therapeutic use ; Clinical Trials as Topic ; Glucosamine/administration & dosage ; Glucosamine/therapeutic use ; Humans ; Joints/drug effects ; Joints/metabolism ; Joints/pathology ; Osteoarthritis/complications ; Osteoarthritis/drug therapy ; Osteoarthritis/metabolism ; Osteoarthritis/pathology ; Pain/drug therapy ; Pain/etiology ; Pain/metabolism ; Pain/pathology
Chemische Substanzen	Analgesics, Opioid ; Anti-Inflammatory Agents, Non-Steroidal ; Cannabinoids ; Glucosamine (N08U5BOQ1K)
Sprache	Englisch
Erscheinungsdatum	2008-04-22
Erscheinungsland	England
Dokumenttyp	Journal Article ; Review
ZDB-ID	1182884-5
ISSN	1744-7658 ; 0967-8298 ; 1354-3784
ISSN (online)	1744-7658
ISSN	0967-8298 ; 1354-3784
DOI	10.1517/13543784.17.5.619
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 3739: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Arthritis and pain. Future targets to control osteoarthritis pain.

Dray, Andy / Read, Simon J

Arthritis research & therapy

2007 Band 9, Heft 3, Seite(n) 212

Abstract: Clinical presentation of osteoarthritis (OA) is dominated by pain during joint use and at rest. OA pain is caused by aberrant functioning of a pathologically altered nervous system with key mechanistic drivers from peripheral nerves and central pain ... ...

Abstract	Clinical presentation of osteoarthritis (OA) is dominated by pain during joint use and at rest. OA pain is caused by aberrant functioning of a pathologically altered nervous system with key mechanistic drivers from peripheral nerves and central pain pathways. This review focuses on symptomatic pain therapy exemplified by molecular targets that alter sensitization and hyperexcitability of the nervous system, for example, opioids and cannabinoids. We highlight opportunities for targeting inflammatory mediators and their key receptors (for example, prostanoids, kinins, cytokines and chemokines), ion channels (for example, NaV1.8, NaV1.7 and CaV2.2) and neurotrophins (for example, nerve growth factor), noting evidence that relates to their participation in OA etiology and treatment. Future neurological treatments of pain appear optimistic but will require the systematic evaluation of emerging opportunities.
Mesh-Begriff(e)	Animals ; Arthralgia/drug therapy ; Arthralgia/etiology ; Humans ; Osteoarthritis/complications ; Osteoarthritis/physiopathology
Sprache	Englisch
Erscheinungsdatum	2007-06-08
Erscheinungsland	England
Dokumenttyp	Journal Article ; Review
ZDB-ID	2107602-9
ISSN	1478-6362 ; 1478-6354
ISSN (online)	1478-6362
ISSN	1478-6354
DOI	10.1186/ar2178
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 5490: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel: Introduction to stroke genomics.

Read, Simon J / Barone, Frank C

Methods in molecular medicine

2003 Band 104, Seite(n) 3–16

Abstract: Translation of the explosion in knowledge of acute ischemic stroke into satisfactory treatment regimens has yet to happen. At present tPA, intra-arterial prourokinase and low-molecular-weight heparin form the vanguard for therapeutic intervention, yet ... ...

Abstract	Translation of the explosion in knowledge of acute ischemic stroke into satisfactory treatment regimens has yet to happen. At present tPA, intra-arterial prourokinase and low-molecular-weight heparin form the vanguard for therapeutic intervention, yet these treatments have a limited therapeutic window. Part of this expansion in understanding has been driven by the contribution of stroke genetics and genomics. However, despite the enormous preclinical and clinical information of receptors, enzymes, second messenger systems, and so forth, that are implicated in stroke pathophysiology, delivery of novel drug treatment has been slow. This introductory chapter discusses the multiple sources of clinical and preclinical genetic information. It will describe the importance of integrating expression information into multiple preclinical models with temporal and spatial roles in lesion pathology and, furthermore developing an understanding of function in the clinic before claiming a role in ischemic stroke. The goal of such a holistic integration of information is to increase the yield from current datasets of gene expression and ultimately to help expand the choice of treatment available to the physician and patient.
Mesh-Begriff(e)	Animals ; Disease Models, Animal ; Gene Expression ; Genomics ; Humans ; Proteins/genetics ; Rats ; Risk Factors ; Stroke/genetics ; Twin Studies as Topic
Chemische Substanzen	Proteins
Sprache	Englisch
Erscheinungsdatum	2003-06-09
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Review
ISSN	1543-1894
ISSN	1543-1894
DOI	10.1385/1-59259-836-6:003
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis.

Isaacs, John D / Cohen, Stanley B / Emery, Paul / Tak, Paul P / Wang, Jianmei / Lei, Guiyuan / Williams, Sarah / Lal, Preeti / Read, Simon J

Annals of the rheumatic diseases

2012 Band 72, Heft 3, Seite(n) 329–336

Abstract: Background: Studies examining the relationship between serological status (rheumatoid factor and/or anticitrullinated antibody) and rituximab treatment outcome in rheumatoid arthritis (RA) have been hampered by limited numbers of seronegative patients.!# ...

Abstract	Background: Studies examining the relationship between serological status (rheumatoid factor and/or anticitrullinated antibody) and rituximab treatment outcome in rheumatoid arthritis (RA) have been hampered by limited numbers of seronegative patients. Objective: To carry out a meta-analysis of trials from the rituximab RA clinical programme to investigate this relationship further. Methods: This was a meta-analysis of four placebo-controlled, phase II or III clinical trials. The efficacy end point in all analyses was change from baseline in Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) at 24 weeks. Assay of serotype and missing data imputation methods were consistent across all studies. Results: The population analysed comprised 2177 patients (rituximab, n=1416; placebo, n=761). Demographics and baseline disease characteristics were well balanced. When a fixed-effects meta-analysis approach was used, the overall-effect model indicated evidence of additional treatment benefit with rituximab in seropositive patients: reduction in DAS28-ESR at week 24 was on average 0.35 units (95% CI 0.12 to 0.84; n=1394) greater than in seronegative patients; this effect was not seen in placebo patients. Heterogeneity indices indicated significant uncertainty in the overall-effect model (Q=8.8, I=0.77; p=0.03 (χ(2) test)). Baseline Health Assessment Questionnaire score, pain visual analogue scale, swollen joint counts of 28 joints and race were significant contributors to this heterogeneity, with additional analysis indicating that these effects may predominate in early RA (methotrexate-naïve) populations. A dominant effect was seen in patients for whom one or more tumour necrosis factor inhibitors had failed. Conclusion: Although the difference was modest, the overall-effect model indicates that seropositive patients respond better to rituximab than seronegative patients.
Mesh-Begriff(e)	Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/blood ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/immunology ; Autoantibodies/blood ; Double-Blind Method ; Humans ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Rheumatoid Factor/blood ; Rituximab ; Treatment Outcome
Chemische Substanzen	Antibodies, Monoclonal, Murine-Derived ; Antirheumatic Agents ; Autoantibodies ; Rituximab (4F4X42SYQ6) ; Rheumatoid Factor (9009-79-4)
Sprache	Englisch
Erscheinungsdatum	2012-06-11
Erscheinungsland	England
Dokumenttyp	Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't
ZDB-ID	7090-7
ISSN	1468-2060 ; 0003-4967
ISSN (online)	1468-2060
ISSN	0003-4967
DOI	10.1136/annrheumdis-2011-201117
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Uh III Zs.114: Hefte anzeigen			Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 167: Hefte anzeigen

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation.

Ivanavicius, Stefan P / Ball, Adrian D / Heapy, Chris G / Westwood, Russell F / Murray, Fraser / Read, Simon J

Pain

2007 Band 128, Heft 3, Seite(n) 272–282

Abstract: Intra-articular injection of mono-iodoacetate (MIA) in the rat knee joint induces a histopathology with similarities to osteoarthritis (OA). Typically, a synovitis (days 1-3) is observed followed by thinning of articular cartilage and subsequent lesion ... ...

Abstract	Intra-articular injection of mono-iodoacetate (MIA) in the rat knee joint induces a histopathology with similarities to osteoarthritis (OA). Typically, a synovitis (days 1-3) is observed followed by thinning of articular cartilage and subsequent lesion of subchondral bone at days 8-14 onwards. Behaviourally, weight-bearing asymmetry is observed, which is sensitive to anti-inflammatory pharmacology at early but not later (days 14+) time points. As subchondral bone is densely innervated, an intriguing possibility is that focal bone pathology may cause neuropathy in this model. In male Wistar rats, activating transcription factor (ATF)-3-immunofluorescence was used as a marker of nerve injury in lumber (L)4 and L5 dorsal root ganglia of the ipsilateral knee. Significantly increased ATF-3-immunoreactivity following MIA treatment was measured in L5 on days 8 and 14 (P<0.05, Kruskal-Wallis and Mann-Whitney U-test), compared to saline controls. Furthermore, in an additional study animals were orally dosed vehicle (5 ml/kg), naproxen (0.3-10 mg/kg), celecoxib (1-10 mg/kg), amitriptyline (3-30 mg/kg) and gabapentin (10-100mg/kg) and evaluated for weight-bearing asymmetry on days 14, 21 and 28 post-MIA. Significant resolution of weight-bearing was observed at high and intermediate doses of amitriptyline and gabapentin at all time points (P<0.05, ANOVA, post-hoc Bonferroni's, vs pre-dose measurements). Transient and weak effects were observed with naproxen (10mg/kg) on days 14 and 28, whereas celecoxib showed no significant effects. Collectively, these data suggest that this putative model of OA is associated with an early phase neuropathy in the L5 innervation territory of the knee.
Mesh-Begriff(e)	Activating Transcription Factor 3/metabolism ; Animals ; Disease Models, Animal ; Gene Expression/drug effects ; Humans ; Hyperalgesia/chemically induced ; Hyperalgesia/metabolism ; Hyperalgesia/pathology ; Iodoacetic Acid ; Male ; Neuralgia/chemically induced ; Neuralgia/metabolism ; Neuralgia/pathology ; Osteoarthritis, Knee/chemically induced ; Osteoarthritis, Knee/metabolism ; Osteoarthritis, Knee/pathology ; Rats ; Rats, Wistar
Chemische Substanzen	ATF3 protein, human ; Activating Transcription Factor 3 ; Iodoacetic Acid (WF5188V710)
Sprache	Englisch
Erscheinungsdatum	2007-02-02
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	193153-2
ISSN	1872-6623 ; 0304-3959
ISSN (online)	1872-6623
ISSN	0304-3959
DOI	10.1016/j.pain.2006.12.022
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 1158: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel: Programmable microchip monitoring of post-stroke pyrexia: effects of aspirin and paracetamol on temperature and infarct size in the rat.

Legos, Jeffrey J / Mangoni, Arduino A / Read, Simon J / Campbell, Colin A / Irving, Elaine A / Roberts, Jenny / Barone, Frank C / Parsons, Andrew A

Journal of neuroscience methods

2001 Band 113, Heft 2, Seite(n) 159–166

Abstract: Background: Recent studies have demonstrated spontaneous and prolonged hyperthermia following stroke in both humans and rodents. However, a full characterization of these pyretic changes and the effects of anti-pyretic drugs on outcome is not available.! ...

Abstract	Background: Recent studies have demonstrated spontaneous and prolonged hyperthermia following stroke in both humans and rodents. However, a full characterization of these pyretic changes and the effects of anti-pyretic drugs on outcome is not available. Methods: The aims of this study were to monitor conscious body temperature (n=10 per group) using programmable microchips for up to 24 h in rats following either permanent (p) or 90 min transient (t) middle cerebral artery occlusion (MCAO) or sham surgery, and to evaluate the relationship to hypothalamic damage. Also, the effects of anti-pyretic drug therapy on body temperature and infarct volume were evaluated in animals treated with vehicle, optimal doses of either aspirin or paracetamol (250 mg/kg i.p.) following pMCAO (n=10 per group). Results: At 1 h, body temperature significantly (P<0.01) increased to 38.6+/-0.2 degrees C following tMCAO and 38.9+/-0.1 degrees C following pMCAO compared with sham-operated animals (37.1+/-0.1 degrees C). Sustained hyperthermia (> or =38.1 degrees C) was observed for up to 24 h following pMCAO but approached baseline within 30 min (37.6+/-0.2 degrees C) following tMCAO with reperfusion. The post-stroke pyrexia was related to the degree of ischemia where hypothalamic damage was observed in (80%) of the animals undergoing pMCAO and (0%) in the tMCAO group (P<0.05). Treatment with paracetamol (250 mg/kg i.p.) significantly attenuated (P<0.05) but did not normalize core body temperature up to 2 h (38.2+/-0.4 degrees C) compared with vehicle treated animals (39.3+/-0.1 degrees C). Aspirin had no effect on temperature under these conditions. Hypothalamic damage and lesion volume were not different between animals treated with paracetamol (253.3+/-8.5 mm(3)), aspirin (264.0+/-11.6 mm(3)) or vehicle (274.4+/-8.2 mm(3)). Conclusions: This study is the first to demonstrate the utility of programmable microchips to monitor serial changes in post-stroke hyperthermia. The sustained post-stroke pyrexia and negative effects of antipyretic treatment may be attributed to the extensive hypothalamic injury suggesting that better pharmacologic approaches to reduce body temperature should be identified and evaluated for brain protection in severe experimental stroke.
Mesh-Begriff(e)	Acetaminophen/pharmacology ; Analgesics, Non-Narcotic/pharmacology ; Animals ; Anti-Inflammatory Agents, Non-Steroidal/pharmacology ; Aspirin/pharmacology ; Body Temperature/drug effects ; Fever/drug therapy ; Fever/pathology ; Fever/physiopathology ; Hypothalamus/pathology ; Hypothalamus/physiopathology ; Infarction, Middle Cerebral Artery/drug therapy ; Infarction, Middle Cerebral Artery/pathology ; Infarction, Middle Cerebral Artery/physiopathology ; Male ; Rats ; Rats, Sprague-Dawley ; Software ; Telemetry/instrumentation
Chemische Substanzen	Analgesics, Non-Narcotic ; Anti-Inflammatory Agents, Non-Steroidal ; Acetaminophen (362O9ITL9D) ; Aspirin (R16CO5Y76E)
Sprache	Englisch
Erscheinungsdatum	2001-12-01
Erscheinungsland	Netherlands
Dokumenttyp	Journal Article
ZDB-ID	282721-9
ISSN	1872-678X ; 0165-0270
ISSN (online)	1872-678X
ISSN	0165-0270
DOI	10.1016/s0165-0270(01)00488-5
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 1486: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Zum Seitenanfang

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Fernleihe an ZB MED

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen